Lilly's experimental drug cuts weight by 21% in diabetes trial
Lilly's experimental drug cuts weight by 21% in diabetes trial Sept 29 (Reuters) - Eli Lilly LLY.N said on Tuesday its experimental drug helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
Recent news on Eli Lilly and
See all newsUS stocks weekly: Spooky
Street View: Next-generation drugs bolster Lilly's growth outlook
US STOCKS-Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
US STOCKS-Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
US STOCKS-Wall Street slides as Alphabet revenue miss revives AI capex jitters